HC Wainwright Lowers Vor Biopharma (NYSE:VOR) Price Target to $13.00

Vor Biopharma (NYSE:VOR) had its price target decreased by HC Wainwright from $17.50 to $13.00 in a report released on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other research firms also recently commented on VOR. Wedbush restated an “outperform” rating and issued a $7.00 price objective on shares of Vor Biopharma in a report on Thursday. Stifel Nicolaus reduced their price target on Vor Biopharma from $12.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday. Finally, JMP Securities reissued a “market outperform” rating and set a $12.00 price target on shares of Vor Biopharma in a research report on Tuesday, December 10th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vor Biopharma presently has a consensus rating of “Buy” and an average target price of $8.86.

Vor Biopharma Price Performance

Vor Biopharma stock opened at $0.87 on Friday. The stock’s 50-day moving average is $1.22 and its 200-day moving average is $1.01. The company has a market cap of $59.75 million, a price-to-earnings ratio of -0.53 and a beta of -0.40. Vor Biopharma has a 12 month low of $0.63 and a 12 month high of $2.43.

Institutional Investors Weigh In On Vor Biopharma

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Two Sigma Investments LP increased its holdings in Vor Biopharma by 18.9% during the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock worth $181,000 after purchasing an additional 25,930 shares during the last quarter. Trustees of Columbia University in the City of New York purchased a new stake in Vor Biopharma during the 4th quarter worth approximately $102,000. RA Capital Management L.P. increased its holdings in Vor Biopharma by 74.3% during the 4th quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company’s stock worth $44,007,000 after purchasing an additional 16,897,159 shares during the last quarter. Northern Trust Corp increased its holdings in Vor Biopharma by 39.0% during the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock worth $175,000 after purchasing an additional 44,252 shares during the last quarter. Finally, Lynx1 Capital Management LP purchased a new stake in Vor Biopharma during the 4th quarter worth approximately $707,000. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.